Association between rapid and sustained remission and clinician- and patient-reported outcomes in patients with rheumatoid arthritis: post hoc analysis of data from the SELECT-COMPARE study.

ABSTRACT:

Background

Rapid remission has been shown to be beneficial in patients with early rheumatoid arthritis (RA). This study assessed the association of rapid and sustained remission with long-term clinician- and patient-reported outcomes (CRO/PROs) in patients treated with b/tsDMARDs.

Methods

This post hoc analysis used pooled data on patients with moderately-to-severely active RA receiving upadacitinib or adalimumab from the SELECT-COMPARE trial (NCT02629159) and its open-label long-term extension (up to 5 years). This study assessed the effect of achieving rapid remission, time to remission, and time in sustained remission on CRO/PROs. Rapid remission was defined as a Disease Activity Score 28 with C-reactive protein (DAS28-CRP) < 2.6 after 12 weeks' treatment. The outcomes of

SUBMITTER: Gossec L 

PROVIDER: S-EPMC12164154 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature